62 
Treating COVID-19: A pharmaceutical executive’s view
McKinsey
MAY 27, 2020
Cedric Francois, the CEO of pharmaceutical company Apellis, discusses possible approaches to treating COVID-19 patients. Insights on Pharmaceuticals & Medical Products
Pharmaceuticals Related Topics 
A ‘GOLD standard’ in brand growth for Japan’s pharmaceutical market
McKinsey
SEPTEMBER 17, 2020
Our GOLD standard will help transform your pharmaceutical brand and achieve accelerated growth. Asia-Pacific
Join
28,000+
INSIDERS
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?
McKinsey
SEPTEMBER 1, 2018
Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.
What’s behind the pharmaceutical sector’s M&A push
McKinsey
OCTOBER 11, 2018
There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights
How Precision Medicine Will Transform the Pharmaceutical and Healthcare Industries
Strategy+Business
FEBRUARY 22, 2018
And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.
Innovating at the speed of the 21st century in pharmaceuticals
McKinsey
OCTOBER 27, 2017
The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights
|
The Pharmaceutical Industry Needs a Customer-Centric Digital Transformation - SPONSOR CONTENT FROM INDEGENE
Harvard Business
SEPTEMBER 28, 2020
Sponsor content from Indegene. Innovation Customer service Technology Sponsor Content
Ten battlegrounds for digital and analytics in life sciences
McKinsey
AUGUST 18, 2020
Insights on Pharmaceuticals & Medical ProductsLife-sciences companies have yet to realize the full potential of digital and analytics. Pioneers are finding success by focusing on entire parts of the business system rather than use case projects.
Designing an agile transformation in pharma R&D
McKinsey
JULY 23, 2019
Pharmaceutical companies are increasingly turning to the concept of agility to help them transform their R&D functions. Insights on Pharmaceuticals & Medical Products
Why tech transfer may be critical to beating COVID-19
McKinsey
JULY 24, 2020
Insights on Pharmaceuticals & Medical ProductsHow quickly COVID-19 vaccine production ramps up will depend on technology transfer—the capabilities and processes that can speed vaccines from development to manufacturing. Are we ready?
.png)
The Bio Revolution: Innovations transforming economies, societies, and our lives
McKinsey
MAY 14, 2020
Insights on Pharmaceuticals & Medical ProductsAdvances in biological science could transform economies and societies, helping to tackle global challenges from climate change to pandemics.
|
The European path to reimbursement for digital health solutions
McKinsey
SEPTEMBER 17, 2020
Insights on Pharmaceuticals & Medical ProductsThe “fail fast and break things” approach that tech start-ups favor probably won’t work in healthcare. A slower, more deliberate route to market and reimbursement is required.
Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN
Harvard Business
MARCH 11, 2018
That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.
How COVID-19 changes the game for biopharma in China
McKinsey
APRIL 25, 2020
Insights on Pharmaceuticals & Medical ProductsBiopharmas should consider five areas as they deal with the crisis.
Medtech’s call to action: Meeting the demand surge caused by COVID-19
McKinsey
SEPTEMBER 2, 2020
Insights on Pharmaceuticals & Medical ProductsFive interventions have helped manufacturers ease supply constraints for medtech products during the pandemic. Important lessons have been learned along the way.
COVID-19 exposes a critical shortage of oxygen in developing countries
McKinsey
AUGUST 27, 2020
Insights on Pharmaceuticals & Medical ProductsThe COVID-19 crisis is exacerbating what is considered a critical vulnerability in the health infrastructure of many developing countries—a severe shortage of medical oxygen.
How US companies are planning for a safe return to the workplace
McKinsey
JUNE 26, 2020
Insights on Pharmaceuticals & Medical ProductsIn a new survey of 100 executives, respondents expect most employees to be working on-site by December. To do so, they are implementing a range of interventions that could transform how people work.
On pins and needles: Will COVID-19 vaccines ‘save the world’?
McKinsey
JULY 30, 2020
Insights on Pharmaceuticals & Medical ProductsInnovators are sprinting to develop inoculations against the novel coronavirus. Here, we summarize the latest information on research timelines and the potential impact of a vaccine on the pandemic—and society.
COVID-19 and cell and gene therapy: How to keep innovation on track
McKinsey
AUGUST 19, 2020
Insights on Pharmaceuticals & Medical ProductsCell and gene therapies promise life-changing treatments, but the pandemic has hit the sector hard. A survey reveals the extent of the disruption and suggests actions to help companies become more resilient.
Creating value from next-generation real-world evidence
McKinsey
JULY 23, 2020
Insights on Pharmaceuticals & Medical ProductsLeading pharma companies are applying advanced analytics to real-world evidence generation to deliver impact at scale. How can leaders keep innovating, and what should others do to catch up?
A vision for medical affairs in 2025
McKinsey
JUNE 13, 2019
Insights on Pharmaceuticals & Medical ProductsFour core areas of medical-affairs activity combine to maximize patient experiences and outcomes.
GSK’s Brian McNamara on the business impact of COVID-19
McKinsey
SEPTEMBER 2, 2020
Insights on Pharmaceuticals & Medical ProductsThe CEO of GlaxoSmithKline Consumer Healthcare discusses the global challenges and possibilities of the next normal and the shifts now underway in consumer behavior.
Bioelectronics ‘jump-start’ the next wave of device therapeutics
McKinsey
OCTOBER 4, 2019
Blurring the lines between pharmaceuticals and medical technology, cybermedicine has the potential to become a pillar of medical treatment and play a key role in the future of medtech innovation. Insights on Pharmaceuticals & Medical Products
Managing China’s growing oncology burden
McKinsey
AUGUST 27, 2020
Insights on Pharmaceuticals & Medical ProductsSignificant increases in incidence rates have made cancer a high priority in China. Progress has resulted from innovative treatments and greater access to care, yet much more needs to be done.
White Coats, Black Scientists
Harvard Business
SEPTEMBER 23, 2020
Race Pharmaceuticals Digital ArticleHow scientific institutions can address systemic racism.
Machine learning and therapeutics 2.0: Avoiding hype, realizing potential
McKinsey
DECEMBER 18, 2018
Insights on Pharmaceuticals & Medical ProductsSix levers can help healthcare and pharma players achieve better outcomes when using machine learning.
Improving patient adherence through data-driven insights
McKinsey
DECEMBER 15, 2018
A McKinsey study points to areas pharmaceutical companies can address to combat this long-standing industry issue. Insights on Pharmaceuticals & Medical ProductsWhen patients fail to follow prescribed medical regimens, outcomes suffer.
Thermo Fisher Scientific CEO Marc Casper on provisioning the front lines in the pandemic
McKinsey
MAY 20, 2020
Governments, healthcare providers, and pharmaceutical companies are battling COVID-19 on different fronts. Insights on Pharmaceuticals & Medical ProductsThermo Fisher Scientific is at the nexus of all of these endeavors.
Driving the next wave of innovation in CAR T-cell therapies
McKinsey
DECEMBER 14, 2019
Insights on Pharmaceuticals & Medical ProductsUnlocking the full potential of CAR T-cell therapies requires investment in four areas.
How Zoetis’s new CEO reset priorities and empowered employees during the pandemic
McKinsey
AUGUST 4, 2020
Insights on Pharmaceuticals & Medical ProductsKristin Peck explains how letting local managers make their own decisions has helped the animal-health company to weather the COVID-19 crisis successfully.
COVID-19: Overcoming supply shortages for diagnostic testing
McKinsey
JULY 15, 2020
Insights on Pharmaceuticals & Medical ProductsTesting is considered critical to containing COVID-19, yet many countries have encountered diagnostic-supply shortages. Understanding where constraints lie could help efforts to scale testing.
Digital therapeutics and pharma: A blueprint for success from Sanofi’s Bozidar Jovicevic
McKinsey
FEBRUARY 14, 2020
Insights on Pharmaceuticals & Medical ProductsSanofi’s global head of digital therapeutics talks about the benefits of digital therapeutics in improving health outcomes in patients.
Programming life: An interview with Jennifer Doudna
McKinsey
JUNE 5, 2020
Insights on Pharmaceuticals & Medical ProductsThe co-discoverer of CRISPR-Cas9 speaks with partner Michael Chui about how genetics technology can expand coronavirus testing and what the future holds for the Bio Revolution.
The rise and rise of medtech in Asia
McKinsey
NOVEMBER 9, 2018
Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market?
Biotech in Europe: A strong foundation for growth and innovation
McKinsey
AUGUST 24, 2019
Insights on Pharmaceuticals & Medical ProductsEuropean companies have an opportunity to play a stronger role in the industry by focusing on three factors.
Let's personalize your content